Latest From Oncologie Inc.
The series A fundraising will help Locana bring CRISPR gene editing to diseases with dysfunctional RNA. Artizan and OncoMyx are among the other firms with recent series A rounds.
Tetraphase's plan to downsize may put the company on the same path as now-bankrupt Achaogen. Also, Bain raises $900m for its second life science fund, Provention calls off post-ADA offering and Oncologie raises $80m series B.
Cipla expands on its in-licensing strategy in India with Lilly’s insulin glargine product, while Aptose signs second agreement with CrystalGenomics to add Chinese rights for leukemia candidate CG-806, and Yakult gains Japanese rights to Verastem's duvelisib.
Sanofi completes the transition of its infectious disease unit to Evotec. Perhaps not yet done with virology, Gilead licenses technology for HIV/hep B vaccines from Hookipa.
- Large Molecule
- Therapeutic Areas
- North America
- Company Type
- Parent & Subsidiaries
- Oncologie Inc.
- Senior Management
Laura E Benjamin, PhD, CEO
David Malek, CBO
Hagop Youssoufian, MD, Acting CMO
Jessicca Rege, PhD, Chief Dev. Officer
- Contact Info
Phone: (781) 907-7810
400 Totten Pond Rd.
Waltham, MA 02451
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.